Sun Pharma shares have seen a significant rise following USFDA approval for ILUMYA.
Ashika Global Securities acquisition news highlights a significant 26% stake in Resurgent India Rating, showcasing growth potential.
Sun Pharma shares have seen a significant rise following USFDA approval for ILUMYA.
Ashika Global Securities acquisition news highlights a significant 26% stake in Resurgent India Rating, showcasing growth potential.